by James Barrett
Daily Wire
Gilead Sciences Inc. revealed Monday its pricing plans for its highly anticipated Covid-19 treatment, remdesivir, including higher prices for Americans with private insurance and lower costs for U.S. government health programs as well as those provided by other developed countries.
The drugmaker disclosed Monday that it will charge $390 per dose for those on a U.S. government health plan, like Medicare, and $520 per dose — a third more than the government cost — for patients with a private insurance plan.